Shares of Pfizer dropped about 2% after the pharma giant decided to scrap its high-profile cholesterol drug bococizumbab. Large clinical trials revealed that the effectiveness of the injectable medicine has waned over time. The decision has also force the company to cut its 2016 earnings forecast. According to Pfizer, bococizumab gradually lost its potency in … Continue reading “Pfizer (PFE) Just Ditched Its High-Profile Cholesterol Drug”
